ESG - Cancer and the Combination Approach
Oncology is a tricky sector in which to innovate, but we can start by optimizing existing combination approaches
NORTHAMPTON, MA / ACCESSWIRE / March 28, 2024 / Jazz Pharmaceuticals
Liz Henderson, Sr. Vice President Technical Operations at Jazz Pharmaceuticals discusses pioneering innovation in oncology and the importance of the manufacturing infrastructure to help achieve drug development goals.
Originally published by the Medicine Maker
Historically, innovation in the pharmaceutical industry has centered around the discovery of active pharmaceutical ingredients. A new, potentially life-saving treatment, however, can only make a difference if physicians can access a reliable supply. Drug shortages in oncology are not new. The global COVID-19 pandemic saw an increase in critical supply chain issues in the manufacture of drugs, which even further underscored the need for continued advancements in the manufacturing of oncology medicines.
Continue reading here
View additional multimedia and more ESG storytelling from Jazz Pharmaceuticals on 3blmedia.com.
Contact Info:
Spokesperson: Jazz Pharmaceuticals
Website: https://www.3blmedia.com/profiles/jazz-pharmaceuticals
Email: info@3blmedia.com
SOURCE: Jazz Pharmaceuticals
View the original press release on accesswire.com